LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.5

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.41

Max

1.52

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+168.67% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	137M 631M
Eelmine avamishind	1.5
Eelmine sulgemishind	1.5

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. veebr 2026, 22:04 UTC

Tulu

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26. veebr 2026, 23:55 UTC

Market Talk

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26. veebr 2026, 23:37 UTC

Market Talk

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26. veebr 2026, 23:32 UTC

Tulu

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26. veebr 2026, 23:19 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26. veebr 2026, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26. veebr 2026, 23:12 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

26. veebr 2026, 23:12 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26. veebr 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26. veebr 2026, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 22:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. veebr 2026, 22:43 UTC

Market Talk

RBA Hike In March Is Being Underpriced -- Market Talk

26. veebr 2026, 22:33 UTC

Omandamised, ülevõtmised, äriostud

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26. veebr 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26. veebr 2026, 22:13 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26. veebr 2026, 21:59 UTC

Tulu

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26. veebr 2026, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. veebr 2026, 21:49 UTC

Tulu

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26. veebr 2026, 21:45 UTC

Tulu

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26. veebr 2026, 21:44 UTC

Tulu

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26. veebr 2026, 21:44 UTC

Tulu

Coles Expects Market to Remain Highly Competitive

26. veebr 2026, 21:44 UTC

Tulu

Coles Says Supermarket Customers Remain Value Oriented

26. veebr 2026, 21:43 UTC

Tulu

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26. veebr 2026, 21:43 UTC

Tulu

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26. veebr 2026, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26. veebr 2026, 21:41 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

168.67% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 168.67%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.